Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a ...

The beat is a boost for the drugmaker as the wider sector braces for U.S. tariffs on pharmaceutical imports and navigates ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.